An Adverse Event Report Routed in Ninety Seconds

Regulated intake looks like a paperwork problem and behaves like a coordination problem. The clock starts the moment a report is received by anyone at all, and most of what happens next is the report sitting still, waiting for a human to decide what it is and where it goes.

A patient calls a support line on a Thursday evening to say that a few hours after her first dose of a newly prescribed medicine she felt her heart race and had to sit down on the kitchen floor until it passed. The person who takes the call is a contract agent whose job is to be kind, capture the details accurately, and open a ticket, and she does all three well. What she cannot do, at that hour and from that seat, is decide whether what she has just heard is an ordinary product complaint or a serious adverse event that has quietly started a regulatory clock ticking against the company that makes the drug. So the ticket drops into a queue, tagged for the safety team to review in the morning, and the single most consequential fact about it — that as of the moment the agent answered the phone the company is now legally aware of a possible case — is already true and completely invisible to everyone who could act on it.

That moment of first receipt is what pharmacovigilance calls Day 0, and it is unforgiving. For a serious and unexpected reaction, a company generally has fifteen calendar days to assess, code, and submit the case to regulators; for a death or a life-threatening event, seven. The clock does not start politely, when the safety team opens the ticket during business hours. It starts when anyone in the organization — a call-center agent, a sales representative, a medical liaison, a shared mailbox nobody reads on the weekend — first becomes aware of the four things that turn a report into a valid case: an identifiable patient, an identifiable reporter, a suspect product, and an event. Everything that happens between that instant and the moment a qualified reviewer actually engages with the case is pure latency, and in most safety operations that latency is measured in hours and sometimes days, not in the ninety seconds it would take a system that was genuinely paying attention from the first word.

Intake is where the clock leaks

Walk a single adverse-event report from the phone call to the regulator and the familiar shape appears, the one that shows up in every operation whose real work is coordination rather than any one difficult task. The report has to be triaged for seriousness, entered into a safety database, coded against MedDRA so that "my heart was racing" becomes a standardized term a regulator will recognize, assessed for expectedness against the product's reference safety information, written up as a coherent clinical narrative, reviewed by someone with medical authority, and finally transmitted into FAERS or EudraVigilance in the right format before the clock runs out. Each of those steps, taken on its own, is something a trained person can do without heroics. What consumes the days is not the steps but the spaces between them — the case waiting in a triage queue, the handoff from intake to a case processor, the reconciliation of a call-center note with a database field with a coding dictionary, each holding a fragment of the same truth and none of them talking to the others without a human to carry the message across.

The pressure on those seams is not holding steady; it is growing in every direction at once. Reports arrive through more channels than a safety team can reasonably watch — call centers, patient support programs, sales forces, medical information lines, published literature, and increasingly the open web — and each new product, each new market, and each new indication adds volume without adding hours to the day. For a long time the industry's answer was better software of a particular kind: a validated safety database, then intake forms to feed it, then workflow tools to move a case from one status to the next. All of it helped and none of it touched the core problem, because that generation of software automated the recording of each step and left the judgment between the steps — is this serious, does this match the label, what happens next — sitting on a human being's desk. The database got faster at storing a case. It never got any faster at deciding what the case was, and deciding what the case is, quickly and correctly, is the entire game when the clock started before anyone qualified had even looked.

Speed without traceability is a different kind of failure

It would be tempting to conclude that the fix is simply to go faster, to point a capable model at the inbound flow and let it classify at machine speed, and in an ordinary business that might even be enough. Pharmacovigilance is not an ordinary business. It operates under regimes — 21 CFR Part 11, good pharmacovigilance practice, the expectations of an inspector who may arrive years later — in which how a decision was reached matters exactly as much as the decision itself. Every action taken on a case must be attributable to a specific actor, time-stamped, and reconstructable long after the fact, because the record is not a byproduct of the work; the record is what a company hands an auditor to prove the work was sound. A system that classifies a report in ninety seconds but cannot show, step by step, why it called the event serious and how it arrived at the coded term has not solved the problem. It has created a faster way to fail an inspection.

This is the specific place where much of what is currently sold as automation quietly comes apart, and the industry's own analysts have started saying so out loud. Gartner has predicted that over forty percent of agentic AI projects will be canceled by the end of 2027, pointing among other things to what it calls "agent washing" — older tools relabeled as autonomous without the underlying substance changing. In a regulated intake process the gap between the label and the substance is brutally clear. A rule that fires an alert or a model that returns a classification is still an unaccountable black box the moment a reviewer asks it to defend itself, and in this domain something will always ask it to defend itself. The requirement is therefore stricter than mere autonomy: the system has to reason its way through a case and simultaneously produce the auditable trail of that reasoning, so that speed and traceability stop being a trade-off and become two outputs of the same act.

Autonomy that both moves and remembers

What closes the gap is not a faster form or a louder alert but a workforce that can carry the coordination end to end while writing down everything it does as it does it. On an Enterprise AI Platform built for this, the Thursday-evening call is read the instant it lands: Autonomous AI Workers parse the narrative, extract and confirm the four minimum criteria that make it a valid case, code the reaction to MedDRA, weigh it for seriousness and expectedness against the product's reference safety information drawn from Enterprise Knowledge, draft the initial narrative, and — critically — start the regulatory clock explicitly rather than letting it run in the dark. Specialist Agents handle the parts that are genuinely mechanical, while the medical judgment that must belong to a person is routed to a qualified reviewer with the case already assembled, so the Human-in-the-Loop spends their scarce attention on the assessment that was always the actual job rather than on the reconstruction that never should have been. Because the Reasoning Core records its Observations as it works, the ninety-second triage arrives with its own audit trail attached — every extraction, every coding decision, every seriousness call time-stamped and attributable, ready for the inspector who may ask about it years from now.

This is the shape of the shift that a growing number of regulated operators mean when they describe the move toward an autonomous enterprise: not a smarter intake screen, but an operation that owns the distance between the moment a report is received and the moment a qualified human engages with it, and that treats the closing of that distance and the documentation of it as the same motion. The point is not to remove clinical judgment from pharmacovigilance, which would be both illegal and foolish. The point is to remove the latency around the judgment — the hours a case spends waiting to be understood — so that a serious signal buried in a Thursday-evening phone call reaches the right reviewer before the weekend rather than after it, with the fifteen-day clock barely touched.

The reframing worth carrying out of all this is that regulated intake was never really a matter of processing cases, and measuring a safety operation by how many cases it clears describes the symptom while hiding the disease. The number that matters is the gap between when a report is received by anyone and when someone qualified actually engages with it, because that gap is where regulatory clocks quietly burn and where a serious event can sit unrecognized in a queue. The operations that understand this will stop asking how many cases their people can push through and start asking how much of the intake runs itself — and, in the same breath, whether the system doing the running can prove every step it took. In a domain where speed and traceability were always assumed to pull against each other, the surprising and durable insight is that the same system that finally makes intake fast is the one that finally makes it defensible, and a report routed in ninety seconds with its reasoning written down beats one triaged in three hours with none.